Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity
about
Natural products as aromatase inhibitorsA Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer.Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells.Demethylation of promoter C region of estrogen receptor alpha gene is correlated with its enhanced expression in estrogen-ablation resistant MCF-7 cells.Pathways to tamoxifen resistance.Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors.The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancerDifferential gene expression in tamoxifen-resistant breast cancer cells revealed by a new analytical model of RNA-Seq dataSoy and breast cancer: focus on angiogenesis.Evolutionary strategy for systemic therapy of metastatic breast cancer: balancing response with suppression of resistanceDifferences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance?Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor alpha gene expression via p38MAPK/CK2 signaling in human breast cancer cells.Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells.A cluster of noncoding RNAs activates the ESR1 locus during breast cancer adaptation.DNA stabilization by the upregulation of estrogen signaling in BRCA gene mutation carriers.What do we know about the mechanisms of aromatase inhibitor resistance?Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.The pitfall of the transient, inconsistent anticancer capacity of antiestrogens and the mechanism of apparent antiestrogen resistanceThe development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistanceFemara and the future: tailoring treatment and combination therapies with Femara.Estrogen Regulates MAPK-Related Genes through Genomic and Nongenomic Interactions between IGF-I Receptor Tyrosine Kinase and Estrogen Receptor-Alpha Signaling Pathways in Human Uterine Leiomyoma Cells.Pharmacological activation of estrogen receptors-α and -β differentially modulates keratinocyte differentiation with functional impact on wound healingClinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer.Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.Aromatase inhibition 2013: clinical state of the art and questions that remain to be solvedEstrogen plus progestin therapy and breast cancer in recently postmenopausal women.Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study.Membrane estradiol signaling in the brain.Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors.Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer.A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer.Biological reprogramming in acquired resistance to endocrine therapy of breast cancer.Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells.Improving Therapeutic Potential of Farnesylthiosalicylic Acid: Tumor Specific Delivery via Conjugation with Heptamethine Cyanine Dye.
P2860
Q24620153-B8FECFD3-F67A-435E-A680-EB394F8BBC02Q30355029-CF87D4B2-91D6-4BBA-9237-693E92083955Q30440238-AEC2BDFF-8D44-47BC-B5BE-156E3EDA9CF5Q30440243-39512735-0D5B-4AB5-86DB-E00AF4C2B3E0Q30441001-9ADEE99C-0E8A-4F09-9BE8-01277829DD28Q33315228-4A0A83BB-4C10-4BFA-B1EB-4D2EB252DC83Q33862290-1E5ADF70-E76D-4921-9AA3-E5EBA9114068Q34356351-AEF6E94A-7AF6-4A59-9D19-38FF5426A413Q34477740-40ADE56B-2807-438D-A249-1CF5EB892275Q34650211-775F5F0C-412C-4FC8-8C63-883236EB079CQ34745884-380D8E11-D78E-4C4C-B1D6-17405F4D7D6DQ34979448-3DBA18C5-704E-49B5-A3AF-0AE25186429DQ35115629-3BBBB86D-DCCD-4E11-80FC-9845062D2ED5Q35168124-C3C141A7-42E7-405A-B673-50A7BD7CF9DBQ35225077-99DBEA22-5516-483E-AB52-369B36568AF9Q35235623-1C9F88F9-BBB1-45B7-807A-F69884ED8399Q35574894-3FD09754-CA24-4E8C-99E7-29DC6EE23786Q35633272-D475829B-B2F9-4E51-8C53-F9C874921F02Q35691554-E7E3E7E0-F376-46D7-89AE-AC81BD96B878Q35752065-84724D93-0EC3-42F2-A1E0-72A145B9033AQ35939435-E1980666-E7F8-4716-9762-552D6EE444B1Q36013029-28FDF1BC-6019-43B6-BE03-DB8B2CF7C26DQ36026429-E6F76333-BBAC-4B1B-A325-D0C0EF00D1BAQ36326856-2BC0BF66-722B-465A-BEB5-602E1D25CBFEQ36393989-C7DE0CD3-E6F3-4CB3-BCAF-524EC42B6E6DQ36458731-B5D7EF2F-5E7A-494D-BA7C-79F1C8CFEF71Q36574547-F6544409-C3BF-4B5C-B4C3-D20093042144Q36589865-BF544C60-6F82-412A-8464-CABD3D346EFCQ36933778-A685A8DF-75BB-4DC2-8287-C4A70DB485CDQ36946008-93042F97-7CC2-4853-B752-366D8113CD26Q37163009-6D01E4DD-638F-406D-8FD5-83ADCDCFB94AQ37182310-BD167E87-546F-45E9-A9DD-713C88315280Q37288111-AB8EF10A-7E26-49BE-8053-CF7DF8AF893DQ37401534-4BF2E4F9-33CA-43A4-9029-53B365EF10B9Q38044021-5D09C9B3-2AC7-4B87-B387-099B4DA8A1D7Q39297345-26D001D0-A331-4E9D-9266-EF6337D3D407Q39520887-6E1E67FA-026F-4363-B24D-0FA38253506BQ39667297-9436DA79-437A-46BA-BBE1-D1064AA91495Q39671678-097C6491-3228-4360-BBF8-6D8F8424FC78Q46685190-3930B3CD-5F9E-4140-B97A-233E601CADD2
P2860
Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Long-term estradiol deprivatio ...... enhances estrogen sensitivity
@ast
Long-term estradiol deprivatio ...... enhances estrogen sensitivity
@en
Long-term estradiol deprivatio ...... enhances estrogen sensitivity
@nl
type
label
Long-term estradiol deprivatio ...... enhances estrogen sensitivity
@ast
Long-term estradiol deprivatio ...... enhances estrogen sensitivity
@en
Long-term estradiol deprivatio ...... enhances estrogen sensitivity
@nl
prefLabel
Long-term estradiol deprivatio ...... enhances estrogen sensitivity
@ast
Long-term estradiol deprivatio ...... enhances estrogen sensitivity
@en
Long-term estradiol deprivatio ...... enhances estrogen sensitivity
@nl
P2093
P356
P1476
Long-term estradiol deprivatio ...... enhances estrogen sensitivity
@en
P2093
A Masamura
J Lawrence
L Berstein
R J Santen
P304
P356
10.1677/ERC.1.01018
P407
P478
12 Suppl 1
P577
2005-07-01T00:00:00Z